Title:

DeGlyPHER: an ultrasensitive method for analysis of viral spike N-glycoforms

Authors:

Sabyasachi Baboo*, Jolene K Diedrich, Salvador Martínez-Bartolomé, Xiaoning Wang, Torben Schiffner, Bettina Groschel, William R Schief, James C Paulson & John R Yates III*

Affiliations:

Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA

Sabyasachi Baboo, Jolene K Diedrich, Salvador Martínez-Bartolomé, Xiaoning Wang, James C Paulson and John R Yates III

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA

Torben Schiffner, Bettina Groschel, William R Schief, James C Paulson

IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA

Torben Schiffner, Bettina Groschel, William R Schief

The Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of

Technology and Harvard, Cambridge, MA, USA

Torben Schiffner, William R Schief

Present address:

Institut für Wirkstoffentwicklung, Universität Leipzig, Leipzig, Germany

Torben Schiffner

Corresponding authors:

Correspondence to Sabyasachi Baboo (sbaboo@scripps.edu) or John R Yates III (jyates@scripps.edu)

Keywords:

proteomics, mass spectrometry, Proteinase K, N-glycan, heterogeneity, HIV, *Env*, viral spike

Abstract:

Viruses can evade the host immune system by displaying numerous glycans on their surface “spike-proteins” that cover immune epitopes. We have developed an ultrasensitive “single pot” method to assess glycan occupancy and the extent of glycan processing from high-mannose to complex forms at each N-glycosylation site. Though aimed at characterizing glycosylation of viral spike-proteins as potential vaccines, this method is applicable for analysis of site-specific glycosylation of any glycoprotein.

Introduction:

Viral spike-proteins initiate virus entry into host cells and are the primary targets of vaccine design. Spike-proteins are often heavily N-glycosylated which help to shield the protein from the host immune response¹. These glycans add complexity to the production and characterization of recombinant protein-based vaccines². This is particularly a concern for characterization of the envelope spike-protein (*Env*) of the Human Immunodeficiency Virus (HIV) comprising a trimer with each monomer containing 26-30 unique N-linked glycosylation sites (NGS) as defined by

the sequon NX [S|T], where X is any amino acid except P³. To address this analytical challenge several mass spectrometry-based strategies using multiple proteases⁴⁻⁶ have been implemented to create sufficient numbers of peptides unique to each glycosylation site^{3,7,8}. In these strategies, individual aliquots are digested with each protease and analyzed separately by liquid chromatography-mass spectrometry (LC-MS/MS), or pooled and analyzed together. To broadly characterize the nature of the glycosylation at each NGS, we had previously introduced the use of endoglycosidases that create residual mass signatures³. This helped us to determine the degree of glycan occupancy, and the degree of glycan processing – from the high mannose form that is initially attached to the protein, which may mature into the complex form when mannose residues are replaced by “terminal” monosaccharide sequences. To achieve coverage for all NGS, we had combined several digestions performed with different proteases and achieved >95% sequence coverage. Here we show that it is possible to replace these multiple proteolytic digestions with a single Proteinase K (PK) digestion, and moreover through careful choice of volatile buffers we have developed an improved “single pot” strategy with significantly increased sensitivity. We name this strategy to analyze glycoforms as DeGlyPHER (*Deglycosylation-dependent Glycan/Proteomic Heterogeneity Evaluation Report*).

Results and Discussion:

PK is a broadly specific serine-protease that has previously been exploited for its potential to generate overlapping peptides and high sequence coverage⁹. The redundancy afforded by overlapping sequences significantly increases confidence in identifications, especially when covalent modifications are present⁴. However, because proteinase K is an aggressive protease it is necessary to attenuate its proteolytic activity to obtain high sequence coverage of proteins.

Attenuation of PK can be achieved using suboptimal reaction conditions⁹ (to reduce the rate of enzyme activity) and limited reaction time. Using a mildly acidic, chaotrope-free solution to attenuate the activity of PK, we were able to achieve >95% sequence coverage of candidate viral spike-proteins and identify all NGS. The proteomic strategy of DeGlyPHER is conceptually similar to our previous approach³, but it is significantly faster and more sensitive. These improvements result from three key changes to the strategy: [1] using only mass spectrometry-compatible constituents, samples are processed in a single solution except the final step of PNGase F deglycosylation; [2] reaction volumes are kept to a minimum (5-8 μ l) to increase the rate of reaction to limit sample loss on surfaces and minimize freeze-drying time; and [3] the use of PK provides faster digestion and excellent sequence and NGS coverage with less starting material. DeGlyPHER reduces sample preparation time from 3 days to 1 day, reduces LC-MS/MS run times by 9 to 24-fold, and can achieve 90-180 times higher sensitivity than existing methods^{3,7,8}. In addition, we have developed the data analysis tool GlycoMSQuant which further reduces analysis times and simplifies data analysis.

We tested DeGlyPHER on BG505 SOSIP.664 MD39¹⁰, a stabilized native-like HIV *Env* trimer being developed for an HIV vaccination strategy¹¹ targeting germline precursors of broadly neutralizing antibodies (bNAbs) that are impacted by N-glycans. As in our previous approach³, the glycosylated peptides generated by PK digestion were sequentially deglycosylated; first with Endo H to remove high-mannose and hybrid N-glycans, and then with PNGase F, which removes all remaining N-glycans. The resulting residual masses on asparagine (N) in NGS is +203 Da at sites occupied by high-mannose/hybrid N-glycans or +3 Da at sites occupied by complex N-glycans when PNGase F deglycosylation is carried out in the presence of H₂¹⁸O

(differentiating these sites from any deamidated Ns). Unoccupied NGS results in no (+0 Da) residual mass on N. Using DeGlyPHER (**Fig. 1a**), we achieved >99% amino acid sequence coverage and identified all theoretically possible 27 NGSs from a single LC-MS/MS run of 0.5 µg of peptides generated from a starting material of 5 µg purified protein (**Fig. 1b** and **Supplementary Figures 1a,b**). We used semi-quantitative label-free analysis based on precursor peak areas to calculate the proportion of N-glycan occupancy (unoccupied: complex: high-mannose/hybrid N-glycans) for each NGS. We reanalyzed the N-glycan microheterogeneity pattern on BG505 SOSIP.664¹² HIV *Env* trimer from data obtained using our previous approach³ and compared it with results using DeGlyPHER (**Supplementary Figures 2**). The results with DeGlyPHER were highly comparable to those using our original approach, in spite of being processed differently and the samples being prepared at different times in different laboratories.

Initial results demonstrated that DeGlyPHER is at least 18 times more sensitive than our previous approach³ even though it uses a simpler and shorter workflow. To evaluate the limit of sensitivity of DeGlyPHER, we processed progressively decreasing amounts of starting material, ranging from 1 µg to 5 ng. We observed that a single LC-MS/MS run with 1 µg of starting material was enough to cover >95% of the amino acid sequence and all NGS (**Fig. 2a**), which is 90 times more sensitive than our previous approach³. Major differences in microheterogeneity at each NGS were generally observed when we started with <100 ng material (**Supplementary Figure 1c**). This is likely due to low sampling as evidenced by a decrease in amino acid sequence and NGS coverage (**Fig. 2a**), as well as the absolute number of identified peptides representing each NGS (**Supplementary Figure 1d**).

DeGlyPHER is agnostic to mass spectrometry platform (**Fig. 2b**). A timsTOF Pro mass-spectrometer coupled to an Evosep One HPLC (timsTOF/Evosep)¹³ was used to achieve >99% sequence coverage and identification of all NGS using a single LC-MS/MS run with 0.5 µg of starting material and an 88-minute LC gradient (**Fig. 1c** and **Supplementary Figures 3a,b**). Thus, the sensitivity of DeGlyPHER on this platform was 180 times higher than our previous approach³.

N-glycan heterogeneity reflects the immunogenicity of the viral spike-protein and is critical for designing vaccines¹⁴. The reproducibility of N-glycan heterogeneity patterns obtained with DeGlyPHER suggests that this is a robust procedure. Variability in sequence coverage is not observed until the limits of detection are reached on an LC-MS/MS platform. Although our results within the same LC-MS platform were reproducible (except some variations when using different proteases, **Supplementary Figure 5**), we may infer the effects of sampling differences when comparing two different LC-MS platforms (QE-HFX vs. timsTOF/Evosep), as in case of N156, N160, N197, N386, N392 (relative peptide abundance is persistently low) and N88, N295, N301, N332, N355, N406, N411 (possible skewing of timsTOF/Evosep identification against N+203 peptides when peptide sampling per NGS decreases due to less starting material) (**Fig. 2b** and **Supplementary Figures 1c,d** and **3c,d**). When enough sampling per NGS is achieved, these variations are diminished (**Figs. 1b,c**).

We attribute improvements in DeGlyPHER to efficient sample handling strategies. We observed reduced sequence coverage if the sample was from the digestion of a small amount of starting material rather than an equal aliquot from a larger sample (**Supplementary Figure 3e**). We infer

that the sensitivity differences are not occurring during LC-MS/MS, but that sample is being lost to the reaction-tube surface (during reaction and lyophilization) and the proportion of loss is more pronounced when we start with less material. The kinetics of the enzyme-substrate reaction may also account for sensitivity differences since a more “crowded” reactant environment (low reaction volumes) is expected to result in better reaction kinetics¹⁵.

The simplicity and high reproducibility of DeGlyPHER will allow for high-throughput analyses of viral spike-proteins and for any glycoprotein whether produced recombinantly or purified from natural sources. Results were highly comparable in the two LC-MS/MS platforms we used. A single analysis using a QE-HFX/nLC platform can determine the complete N-glycan heterogeneity pattern from 1 microgram of purified viral spike-protein. The timsTOF/EvoSep platform was observed to be more sensitive than QE-HFX/nLC across all NGS, although limited sampling may not allow us to confidently infer N-glycan microheterogeneity at all NGS. We view the high sensitivity of DeGlyPHER to be an important step to analyze glycosylation of more complex samples such as whole virus or virus in infected blood¹⁶.

Methods:

Expression and purification of HIV *Env* trimers

BG505 SOSIP.664¹² and BG505 SOSIP.664 MD39¹⁰ *Env* trimers were expressed and purified essentially as described previously¹⁰. Briefly, sequences with codons optimized for expression in human cells were synthesized and cloned into pHLSec between *AgeI*/*KpnI* by Genscript. The constructs were co-transfected with Furin-encoding plasmid, using polyethylenimine in Freestyle 293F cells cultured in 293 FreeStyle media (Thermo Fisher Scientific). Where indicated, 15 μ M

sterile-filtered Kifunensine (Cayman Chemical) was added after transfection. After 6-7 days, supernatant was collected after passing through 0.22 μ m filter (Nalgene), and the C-terminally His-tagged trimers were purified using a HisTrap affinity column (Cytiva) with a linear elution gradient from 20-500 mM imidazole, followed by a Superdex 200 Increase SEC column (Cytiva) in Tris-buffered saline/TBS (20 mM Tris, 100 mM NaCl, pH 7.5). The oligomeric state and purity of trimer was verified using size exclusion chromatography coupled with multi-angle light scattering (SEC-MALS; DAWN HELEOS II/ Optilab T-rEX, Wyatt Technology).

Proteinase K treatment and deglycosylation

HIV Env trimer was exchanged to water using Microcon Ultracel-10 centrifugal device (Millipore Sigma). Trimer was reduced with 5 mM tris(2-carboxyethyl)phosphine hydrochloride (TCEP-HCl, Thermo Scientific) and alkylated with 10 mM 2-chloroacetamide (Sigma Aldrich) in 100 mM ammonium acetate for 20 min at room temperature (RT, 24°C). Initial protein-level deglycosylation was performed using 250 U of Endo H (New England Biolabs) for up to 5 μ g trimer, for 1 h at 37°C (pH 5.5-6.0). Trimer was digested with 1:25 Proteinase K (Sigma Aldrich) for 4 h at 37°C (pH 5.5-6.0). PK was denatured by incubating at 90°C for 15 min, then cooled to RT. Peptides were deglycosylated again with 250 U Endo H for 1 h at 37°C (pH 5.5-6.0), then frozen at -80°C and lyophilized. 100 U PNGase F (New England Biolabs) was lyophilized (for up to 5 μ g trimer), resuspended in 100 mM ammonium bicarbonate prepared in H₂¹⁸O (97% ¹⁸O, Sigma-Aldrich), and added to the lyophilized peptides. The resulting 5-8 μ l reaction solutions (except PNGase F reaction, in 5-20 μ l) were then incubated for 1 h at 37°C (pH 8.0-8.5) in 0.2 ml PCR tubes on a thermocycler with heated lid.

Validating efficiency of glycosidases

BG505 SOSIP.664 HIV *Env* trimer glycosylated with only high-mannose N-glycans (purified from cells treated with Kifunensine¹⁷, which inhibits processing of high-mannose N-glycans to complex N-glycans during protein maturation), was sequentially treated with Endo H, followed by PNGase F. After treatment with both enzymes, 99.2% of identified peptides were N+203; 100% of peptides identified with only PNGase F treatment were N+3 (***Supplementary Figures 4a,b***; proportions do not consider unoccupied NGS because they remained similar in both experiments – 8-10%). We realize the possibility that glycosidase PNGase F may occasionally cleave the remnant GlcNAc (N-Acetylglucosamine)¹⁸ post-Endo H processing of high-mannose/hybrid N-glycans and thus, convert the mass modification characteristic of high-mannose/hybrid (+203) to complex (+3) N-glycans, which would affect our analyses. However, we have not observed any significant evidence of this possibility in our results, though it may explain why we observe a few peptides with +3 mass modified NGS in Kifunensine treated samples (***Supplementary Figure 4a***).

Trypsin proteolysis

The Proteinase K/deglycosylation method described above was followed, except PK was replaced with trypsin and reactions were incubated overnight at 37°C. Trypsin generated a lower total number of peptides than PK, but we obtained >95% sequence coverage, including 26 of 27 NGS (***Supplementary Figure 5a***). Variations in N-glycan microheterogeneity at certain NGS may be explained by low sampling at these sites (N386, N392) or difference in cleavage-specificity between PK and trypsin (N88, N611) (***Supplementary Figures 5b,c***).

LC-MS/MS

Q Exactive HF-X with EASY-nLC 1200

Samples were analyzed on an Q Exactive HF-X mass spectrometer (Thermo). Samples were injected directly onto a 25 cm, 100 µm ID column packed with BEH 1.7 µm C18 resin (Waters). Samples were separated at a flow rate of 300 nL/min on an EASY-nLC 1200 (Thermo). Buffers A and B were 0.1% formic acid in 5% and 80% acetonitrile, respectively. The following gradient was used: 1–25% B over 160 min, an increase to 40% B over 40 min, an increase to 90% B over another 10 min and 30 min at 90% B for a total run time of 240 min. Column was re-equilibrated with solution A prior to the injection of sample. Peptides were eluted from the tip of the column and nanosprayed directly into the mass spectrometer by application of 2.8 kV at the back of the column. The mass spectrometer was operated in a data dependent mode. Full MS1 scans were collected in the Orbitrap at 120,000 resolution. The ten most abundant ions per scan were selected for HCD MS/MS at 25 NCE. Dynamic exclusion was enabled with exclusion duration of 10 s and singly charged ions were excluded.

timsTOF Pro with Evosep One

Samples were loaded onto EvoTips following manufacturer protocol. The samples were run on an Evosep One (Evosep) coupled to a timsTOF Pro (Bruker Daltonics). Samples were separated on a 15 cm × 150 µm ID column with BEH 1.7 µm C18 beads (Waters) and integrated tip pulled in-house using either the 30 SPD or 15 SPD methods. Mobile phases A and B were 0.1% formic acid in water and 0.1% formic acid in acetonitrile, respectively. MS data was acquired in PASEF mode with 1 MS1 survey TIMS-MS and 10 PASEF MS/MS scans acquired per 1.1 s acquisition cycle. Ion accumulation and ramp time in the dual TIMS analyzer was set to 100 ms each and we analyzed the ion mobility range from $1/K_0 = 0.6 \text{ Vs cm}^{-2}$ to 1.6 Vs cm^{-2} . Precursor ions for

MS/MS analysis were isolated with a 2 Th window for $m/z < 700$ and 3 Th for $m/z > 700$ with a total m/z range of 100-1700. The collision energy was lowered linearly as a function of increasing mobility starting from 59 eV at $1/K_0 = 1.6 \text{ VS cm}^{-2}$ to 20 eV at $1/K_0 = 0.6 \text{ Vs cm}^{-2}$. Singly charged precursor ions were excluded with a polygon filter, precursors for MS/MS were picked at an intensity threshold of 2,500, target value of 20,000 and with an active exclusion of 24 s.

Data Processing

Protein and peptide identification were done with Integrated Proteomics Pipeline (IP2, Bruker Scientific LLC). Tandem mass spectra were extracted from raw files using RawConverter¹⁹ (timstofCoverter for timsTOF Pro data) and searched with ProLuCID²⁰ against a database comprising UniProt reviewed (Swiss-Prot) proteome for *Homo sapiens* (UP000005640), UniProt amino acid sequences for Endo H (P04067), PNGase F (Q9XBM8), and Proteinase K (P06873), amino acid sequences for BG505 SOSIP.664¹² and BG505 SOSIP.664 MD39¹⁰ (including a preceding secretory signal sequence and followed by 6xHis-tag), and a list of general protein contaminants. The search space included no cleavage-specificity (all fully tryptic and semi-tryptic peptide candidates for trypsin treatment). Carbamidomethylation (+57.02146 C) was considered a static modification. Deamidation in presence of H_2^{18}O (+2.988261 N), GlcNAc (+203.079373 N), oxidation (+15.994915 M) and N-terminal pyroglutamate formation (–17.026549 Q) were considered differential modifications. Data was searched with 50 ppm precursor ion tolerance and 50 ppm fragment ion tolerance. Identified proteins were filtered using DTASelect²¹ and utilizing a target-decoy database search strategy to limit the false discovery rate to 1%, at the spectrum level²². A minimum of 1 peptide per protein and no tryptic

end (or 1 tryptic end when treated with trypsin) per peptide were required and precursor delta mass cut-off was fixed at 10 ppm for data acquired with Q Exactive HF-X or 20 ppm for data acquired with timsTOF Pro. Statistical models for peptide mass modification (modstat) were applied (trypstat was additionally applied for trypsin-treated samples). Census2²³ label-free analysis was performed based on the precursor peak area, with a 10 ppm precursor mass tolerance and 0.1 min retention time tolerance. “Match between runs” was used to find missing peptides between runs for Q Exactive HF-X data (for timsTOF Pro data, reconstructed-MS1 based chromatograms combining isotope peaks for all triggered precursor ions were pre-generated, and then chromatograms were assigned to identified peptides for quantitative analysis, without retrieving missing peptides).

Data Analysis using GlycoMSQuant

Our new tool GlycoMSQuant v.1.4.1 (<https://github.com/proteomicsyates/GlycoMSQuant>) was implemented to automate the analysis and to visualize the results. GlycoMSQuant summed precursor peak areas across replicates, discarded peptides without NGS, discarded misidentified peptides when N-glycan remnant-mass modifications were localized to non-NGS asparagines and corrected/fixed N-glycan mislocalization where appropriate. The results were aligned to NGS in *Env* of HXB2²⁴ HIV-1 variant.

Precursor peak area was calculated by Census2²³ from extracted-ion chromatogram (XIC) for each peptide in each replicate. For each NGS (NX[S|T], where X is any amino acid except P), the “N-glycosylation state” represented by proportions for unoccupied (+0, *u*), complex (+2.988261, *c*) and, high-mannose/hybrid (+203.079373, *h*) N-glycans was calculated as follows.

277

278 The sum of the precursor peak areas $S_{g,pepz}$ was calculated as:

$$279 \quad S_{g,pepz} = \sum xic_{pepz}$$

280 where N-glycosylated peptides with the same sequences and charge were grouped together

281 ($pepz$), g is the N-glycosylation state $\in G(u, c, h)$, and xic is the precursor peak area.

282 For each group ($pepz$), the abundance proportion $\%_{g,pepz}$ of each N-glycosylation state $g \in G$ was
283 calculated as:

$$284 \quad \%_{g,pepz} = \frac{S_{g,pepz}}{\sum_{i \in G} S_{i,pepz}}$$

285 Finally, as each NGS may be covered by multiple groups ($pepz$), the proportion of each N-

286 glycosylation state g for a particular NGS (ngs) is calculated as the mean of all proportions

287 $\%_{g,pepz}$ of all groups ($pepz$) covering this NGS:

$$288 \quad \%_{ngs,g} = \frac{1}{n_{ngs}} \sum \%_{g,pepz}$$

289 where n_{ngs} is the number of groups ($pepz$) covering a particular NGS.

290 The standard error of mean of the proportion of each N-glycosylation state $g \in G$ for a particular

291 NGS ($SEM_{ngs,g}$) was calculated as:

$$292 \quad SEM_{ngs,g} = \frac{s_{ngs,g}}{\sqrt{n_{ngs}}}$$

293 where, $s_{ngs,g}$ is the standard deviation of $\%_{g,pepz}$ from all groups ($pepz$) covering a particular NGS.

294

295 Pairwise statistical comparisons of experiments (a and b) were performed for each $g \in G$ at each

296 NGS using proportion values $\%_{g,pepz}$ of groups ($pepz$) sharing the NGS, applying the Mann-

297 Whitney U test²⁵. Testing $\%_{g,pepz,a}$ vs. $\%_{g,pepz,b}$ individually for u , c and h at each NGS, we

calculated p -values that were subjected to multiple hypothesis correction using the Benjamini-Hochberg (BH) method²⁶. If the corrected p -value was <0.05 (for u , c or h at any NGS), then the difference was considered statistically significant.

For **Supplementary Figure 2**, published data from our previous approach³ was reanalyzed using the data analysis workflow described here. Briefly, the data analyzed is from 3 replicates of 3 conditions, each separately analyzed by LC-MS/MS, with total starting material of 90 μ g protein, and Census2²³ label-free analysis was performed simultaneously on all 9 experiments without “match between runs”, and the results analyzed by GlycoMSQuant. This was compared with data obtained from a single LC-MS/MS run (QE-HFX/nLC) with 0.5 μ g of peptides generated from a starting material of 5 μ g purified protein.

Acknowledgement:

We thank Bruker Daltonics for providing access to timsTOF Pro MS. We thank Bruker Scientific LLC and Robin S Park for making IP2 accessible for data analysis. We thank Titus Jung in J.R.Y. lab for IT support. We thank members of the J.R.Y. lab for discussion and Claire Delahunty for critically perusing the manuscript. We thank Saman Eskandarzadeh, Michael Kubitz, and Erik Georgeson in W.R.S. lab for assistance in protein production. This work was supported by the grants P41GM103533 (NIH) and UM1AI100663, UM1AI144462, R01/R56AI113867 (NIH/NIAID). We thank Bill and Melinda Gates Foundation (BMGF) Collaboration for AIDS Vaccine Discovery (CAVD) funding to IAVI Neutralizing Antibody Center (NAC) and Ragon Institute post-doctoral fellowship to T.S.

Author Contributions:

S.B. conceived the method. S.B., J.K.D. and X.W. designed the experiments. S.B. processed the samples and analyzed data. J.K.D. performed LC-MS/MS. S.M.B. created the GlycoMSQuant tool. T.S. and B.G. expressed and purified HIV *Env* trimers. W.R.S., J.C.P. and J.R.Y. supervised the project. S.B. wrote the paper with contribution from all authors.

Competing Interests:

The authors declare no competing interests.

Data Availability:

Mass spectrometry data has been deposited in MassIVE-KB repository and is also accessible through ProteomeXchange Consortium with identifiers MSV000087414 and PXD025990, respectively.

Code Availability:

GlycoMSQuant source code is freely available at <https://github.com/proteomicsyates/GlycoMSQuant> under a permissive Apache License 2.0.

References:

- 1 Rudd, P. M. & Dwek, R. A. Glycosylation: heterogeneity and the 3D structure of proteins. *Crit Rev Biochem Mol Biol* **32**, 1-100, doi:10.3109/10409239709085144 (1997).

342 2 Burton, D. R. & Hangartner, L. Broadly Neutralizing Antibodies to HIV and Their Role
343 in Vaccine Design. *Annu Rev Immunol* **34**, 635-659, doi:10.1146/annurev-immunol-
344 041015-055515 (2016).

345 3 Cao, L. *et al.* Global site-specific N-glycosylation analysis of HIV envelope glycoprotein.
346 *Nat Commun* **8**, 14954, doi:10.1038/ncomms14954 (2017).

347 4 MacCoss, M. J. *et al.* Shotgun identification of protein modifications from protein
348 complexes and lens tissue. *Proc Natl Acad Sci U S A* **99**, 7900-7905,
349 doi:10.1073/pnas.122231399 (2002).

350 5 Zhang, Y., Fonslow, B. R., Shan, B., Baek, M. C. & Yates, J. R., 3rd. Protein analysis by
351 shotgun/bottom-up proteomics. *Chem Rev* **113**, 2343-2394, doi:10.1021/cr3003533
352 (2013).

353 6 Tsiatsiani, L. & Heck, A. J. Proteomics beyond trypsin. *Febs j* **282**, 2612-2626,
354 doi:10.1111/febs.13287 (2015).

355 7 Behrens, A. J. *et al.* Molecular Architecture of the Cleavage-Dependent Mannose Patch
356 on a Soluble HIV-1 Envelope Glycoprotein Trimer. *J Virol* **91**, doi:10.1128/jvi.01894-16
357 (2017).

358 8 Go, E. P. *et al.* Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein
359 Production Based on Eleven Env Trimers. *J Virol* **91**, doi:10.1128/jvi.02428-16 (2017).

360 9 Wu, C. C., MacCoss, M. J., Howell, K. E. & Yates, J. R., 3rd. A method for the
361 comprehensive proteomic analysis of membrane proteins. *Nat Biotechnol* **21**, 532-538,
362 doi:10.1038/nbt819 (2003).

363 10 Steichen, J. M. *et al.* HIV Vaccine Design to Target Germline Precursors of Glycan-
364 Dependent Broadly Neutralizing Antibodies. *Immunity* **45**, 483-496,
365 doi:10.1016/j.immuni.2016.08.016 (2016).

366 11 Steichen, J. M. *et al.* A generalized HIV vaccine design strategy for priming of broadly
367 neutralizing antibody responses. *Science* **366**, doi:10.1126/science.aax4380 (2019).

368 12 Sanders, R. W. *et al.* A next-generation cleaved, soluble HIV-1 Env trimer, BG505
369 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-
370 neutralizing antibodies. *PLoS Pathog* **9**, e1003618, doi:10.1371/journal.ppat.1003618
371 (2013).

372 13 Meier, F. *et al.* Online Parallel Accumulation-Serial Fragmentation (PASEF) with a
373 Novel Trapped Ion Mobility Mass Spectrometer. *Mol Cell Proteomics* **17**, 2534-2545,
374 doi:10.1074/mcp.TIR118.000900 (2018).

375 14 Seabright, G. E., Doores, K. J., Burton, D. R. & Crispin, M. Protein and Glycan Mimicry
376 in HIV Vaccine Design. *J Mol Biol* **431**, 2223-2247, doi:10.1016/j.jmb.2019.04.016
377 (2019).

378 15 Zhou, H. X., Rivas, G. & Minton, A. P. Macromolecular crowding and confinement:
379 biochemical, biophysical, and potential physiological consequences. *Annu Rev Biophys*
380 **37**, 375-397, doi:10.1146/annurev.biophys.37.032807.125817 (2008).

381 16 Bar-On, Y. M., Flamholz, A., Phillips, R. & Milo, R. SARS-CoV-2 (COVID-19) by the
382 numbers. *Elife* **9**, doi:10.7554/eLife.57309 (2020).

383 17 Scanlan, C. N. *et al.* Inhibition of mammalian glycan biosynthesis produces non-self
384 antigens for a broadly neutralising, HIV-1 specific antibody. *J Mol Biol* **372**, 16-22,
385 doi:10.1016/j.jmb.2007.06.027 (2007).

- 386 18 Fan, J. Q. & Lee, Y. C. Detailed studies on substrate structure requirements of
387 glycoamidases A and F. *J Biol Chem* **272**, 27058-27064, doi:10.1074/jbc.272.43.27058
388 (1997).
- 389 19 He, L., Diedrich, J., Chu, Y. Y. & Yates, J. R., 3rd. Extracting Accurate Precursor
390 Information for Tandem Mass Spectra by RawConverter. *Anal Chem* **87**, 11361-11367,
391 doi:10.1021/acs.analchem.5b02721 (2015).
- 392 20 Xu, T. *et al.* ProLuCID: An improved SEQUEST-like algorithm with enhanced
393 sensitivity and specificity. *J Proteomics* **129**, 16-24, doi:10.1016/j.jprot.2015.07.001
394 (2015).
- 395 21 Tabb, D. L., McDonald, W. H. & Yates, J. R., 3rd. DTASelect and Contrast: tools for
396 assembling and comparing protein identifications from shotgun proteomics. *J Proteome*
397 *Res* **1**, 21-26, doi:10.1021/pr015504q (2002).
- 398 22 Peng, J., Elias, J. E., Thoreen, C. C., Licklider, L. J. & Gygi, S. P. Evaluation of
399 multidimensional chromatography coupled with tandem mass spectrometry (LC/LC-
400 MS/MS) for large-scale protein analysis: the yeast proteome. *J Proteome Res* **2**, 43-50,
401 doi:10.1021/pr025556v (2003).
- 402 23 Park, S. K., Venable, J. D., Xu, T. & Yates, J. R., 3rd. A quantitative analysis software
403 tool for mass spectrometry-based proteomics. *Nat Methods* **5**, 319-322,
404 doi:10.1038/nmeth.1195 (2008).
- 405 24 Zhang, M. *et al.* Tracking global patterns of N-linked glycosylation site variation in
406 highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza
407 hemagglutinin. *Glycobiology* **14**, 1229-1246, doi:10.1093/glycob/cwh106 (2004).

- 25 Mann, H. B. & Whitney, D. R. On a Test of Whether one of Two Random Variables is Stochastically Larger than the Other. *The Annals of Mathematical Statistics* **18**, 50-60 (1947).
- 26 Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society. Series B (Methodological)* **57**, 289-300 (1995).

Figures

Figure 1 | Proteinase K and glycosidase treatment provides N-glycan microheterogeneity in BG505 SOSIP.664 MD39 trimer. (a) DeGlyPHER workflow, resulting in peptides with expected mass modifications at NGS representing N-glycosylation states. **(b)** Pattern observed using 4 h triplicates on a QE-HFX/nLC platform. **(c)** Pattern observed using 88 min triplicates on timsTOF/Evosep platform. N-glycosylation states are color-coded. Error bars represent mean-SEM. Between **(b)** and **(c)**, the pattern is similar, and any significant difference (BH-corrected p -value <0.05) in proportion of a certain N-glycosylation state at an NGS is represented by color-coded *.

Figure 2 | Factors affecting limit of sensitivity. (a) Decreasing trend of sequence and NGS coverage observed as starting material is diluted 200-fold (1 μ g to 5 ng, QE-HFX/nLC) or 100-fold (0.5 μ g to 5 ng, timsTOF/Evosep), using triplicates for each amount of starting material. The limit of sensitivity is revealed. (b) Relative abundance of peptides identified per NGS across the dilution series for the 2 LC-MS/MS platforms used. This comparison reveals a non-uniform digestion pattern that may be attributed to steric hindrance offered by the glycoprotein or characteristic behavior of individual peptides in LC-MS/MS. Error bars represent mean $\pm$ SEM. Values for sequence and NGS coverage are mean